NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Teva Pharmaceutical Industrie
s Limited page 2

 

Note 3 - Property, Plant And Equipment:

A. Composition of assets, grouped by major classifications, and changes therein during 1998, are as follows:

  Cost Accumulated depreciation
  Balance at beginning of year Additions during the year Retirements during the year Other changes (see c) Balance at end of year Balance at beginning of year Depreciation charged during the year Depreciation in respect of retirements during the year Other changes (see c) Balance at end of year Depreciated Balance - December 31
1998 1997
  U.S.$ in thousands U.S.$ in thousands

Land - including leasehold land

16,701

1,817

1,943

20,461

  

 20,461

 16,701

Buildings*

192,617 6,397 (113)

15,099

214,000 43,677 7,282 (25) (334) 50,600 163,400 148,940

Machinery and equipment

 362,413

 29,107

 (7,512)

 17,976

 401,984

 169,663

32,631

(7,690)

 118

 194,722

 207,262

 192,750

Motor vehicles, computer      equipment, furniture and other assets

93,225

15,648

(4,325)

3,756

108,304

41,803

13,348

(2,556)

1,739

54,334

53,970

51,422

Payments on account of fixed assets

7,460

1,570

(102)

961

9,889

 

9,889

7,460

 


672,416


54,539


(12,052)


39,735


754,638


255,143


53,261


(10,271)


1,523


299,656


454,982


417,273

Net of investment grant received, see b. below

8,663

439



9,102

4,353

149



4,502

4,600

4,310

* Includes financial expenses capitalized

11,673

481



 

12,154

1,339

970




2,309

9,845

10,334

 

Rights to leasehold land extend over original periods of 49 years ending in the years 2012-2047.


B.   Investment grants have been received from the State of Israel by Teva and certain of its subsidiaries under the terms of  the Law for the Encouragement of Capital Investments, 1959 (see also note 9a(1)). As security for implementation of the approved projects and compliance with the conditions of the approvals, floating charges have been registered on the above companies' assets in favor of the State of Israel.

 

C.  These changes relate to differences resulting from translation of the financial statements of subsidiaries drawn up in non-dollar currency.

Note 4 - Intangible Assets:

  Original amount Accumulated
amortization
  December 31 December 31
  1998 1997 1998 1997
  U. S. $ in thousands
  Goodwill - in subsidiaries 183,793 93,056 22,324 17,944
 Know-how, patents and product rights 14,485 16,658 3,749 10,154
  198,278 109,714 26,073 28,098

 

Note 5 - Employee Rights Upon Retirement:

a. Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The following principal plans relate to employee rights upon retirement, as applicable to the Group's Israeli companies.

1) Pension plans for the majority of the Company's employees. Under collective labor agreements, these external pension plans provide 72% of the severance pay liability. The pension and severance pay liabilities covered by these plans are not reflected in the financial statements as the pension and severance pay risks have been irrevocably transferred to the pension funds.

2) Insurance policies for employees in managerial positions. These policies provide coverage for severance pay and pension liabilities of managerial personnel. The policies are Company assets and under labor agreements, subject to certain limitations, they may be transferred to the ownership of the beneficiary employees.

3) Pension and severance pay liabilities not covered as above are fully provided for in the Company's financial statements. The Company, at its discretion, deposits monies in funds managed by major Israeli banks which are earmarked as cover for these liabilities.

Employees dismissed before attaining retirement age are entitled to severance pay, computed on the basis of the most recent salary. In the event that the amounts accumulated in the pension and severance pay funds are insufficient to cover severance pay computed as above, Teva and its subsidiaries are obligated to supplement the deficiency. Past experience indicates that the vast majority of employees continue in service until retirement age. Accordingly, management is of the opinion that the liability for supplemental severance pay is insignificant; consequently, no provisions were made.

b. The employees of Pharmachemie in the Netherlands and APS/Berk in the U.K. can participate in the following pension schemes: a defined benefits scheme providing benefits based on final pensionable pay and a defined contribution scheme.

c. Teva USA has various defined contribution plans for the benefit of its employees. Teva USA's contributions under these plans are based on specified percentages of pay.

d. The employees of the Hungarian and Italian subsidiaries are entitled to a retirement grant when they leave the company. In the consolidated accounts, a full accrual of the Company's liability is made based on length of service and remuneration of each employee at the balance sheet date.

e. The balance sheet liability for employee rights upon retirement, and the amount funded, are composed as follows:

  December 31
  1998 1997
  U.S. $ in thousands
  Liability 30,200 32,373
  L e s s amount funded 26,305 27,959
 Unfunded balance 3,895 4,414


Under Israeli GAAP, amounts funded, as above, are deducted from the related severance pay liability. Under U.S. GAAP, the amounts funded should be presented as a long-term investment among the Company's assets.

f. The net amounts of pension and severance pay charged to income in the years 1998, 1997 and 1996 (excluding, in 1998, amounts relating to termination of employment, which were charged to restructuring expenses) were approximately $ 4.7 million, $ 3.8 million and $ 2.6 million, respectively.



 

Click here for the next page